Last €130.75 EUR
Change Today -0.74 / -0.56%
Volume 168.0
As of 10:46 AM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILU) Snapshot

Open
€128.20
Previous Close
€131.49
Day High
€132.86
Day Low
€128.14
52 Week High
07/24/14 - €136.59
52 Week Low
10/9/13 - €54.60
Market Cap
18.2B
Average Volume 10 Days
172.7
EPS TTM
--
Shares Outstanding
139.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ILLUMINA INC (ILU)

illumina inc (ILU) Details

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology are designed to meet the various demands of a range of sequencing applications; and array platforms consist of HiScan and iScan systems that are array scanners, which support the imaging of array-based genetic analysis products. It also offers various sample preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping and whole genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

Founded in 1998

illumina inc (ILU) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.1M
President and Director
Total Annual Compensation: $153.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $447.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $457.1K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $449.6K
Compensation as of Fiscal Year 2013.

illumina inc (ILU) Key Developments

Illumina Announces Strategic Partnerships with AstraZeneca, Janssen and Sanofi to Redefine Companion Diagnostics for Oncology

Illumina, Inc. announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing (NGS)-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca, Janssen Biotech, Inc., and Sanofi. Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners' clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm.

Illumina, Inc. Appoints Jeff Huber to Its Board of Directors

Illumina Inc. announced that Jeff Huber has joined the company's Board of Directors. Mr. Huber is Senior Vice President at Google Inc.

Berry Genomics Co. Selects Illumina's Next-Generation Sequencing Technology

Berry Genomics Co. reported that it has chosen Illumina's next-generation sequencing technology as the platform on which Berry will secure Chinese Food and Drug Administration regulatory approval for clinical applications, thereby expanding access to NGS-based tests in China. The new system integrates Berry Genomics' Bambni assay, which includes a library preparation kit, analysis software, and a sequencing instrument based on Illumina's NextSeq 500 Sequencing System. Berry's proprietary Bambni assay, which has been validated on more than 200,000 samples, utilizes a PCR-free library prep technology and the proprietary RUPA analysis software.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILU:GR €130.75 EUR -0.74

ILU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ILU.
View Industry Companies
 

Industry Analysis

ILU

Industry Average

Valuation ILU Industry Range
No financial data is available for ILU.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.